Summary:
- Climb Bio presented initial Phase 2 clinical trial data for their drug candidate, budoprutug, specifically targeting proteinuric membranous nephropathy (pMN).
- The presentation at the American Society of Nephrology (ASN) Kidney Week highlights significant progress in evaluating the safety and efficacy of this therapeutic intervention for a complex autoimmune kidney disease.